Track market-moving stories before they get noisy

Posted by Defense World Staff on Apr 26th, 2026

Cwm LLC boosted its stake in Envista Holdings Corporation (NYSE:NVST – Free Report) by 55.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,217 shares of the company’s stock after buying an additional 25,905 shares during the period. Cwm LLC’s holdings in Envista were worth $1,568,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in NVST. Holocene Advisors LP acquired a new position in shares of Envista during the second quarter valued at $43,936,000. Alliancebernstein L.P. increased its holdings in shares of Envista by 34.0% during the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after purchasing an additional 1,547,656 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Envista during the third quarter valued at $24,260,000. Integral Health Asset Management LLC acquired a new position in shares of Envista during the third quarter valued at $11,204,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Envista by 22.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,149 shares of the company’s stock valued at $59,178,000 after purchasing an additional 523,949 shares during the period.

Wall Street Analysts Forecast Growth NVST has been the topic of a number of research analyst reports. Robert W. Baird set a $30.00 price target on Envista in a report on Friday, February 6th. Wall Street Zen raised Envista from a “buy” rating to a “strong-buy” rating in a report on Monday, January 26th. Stifel Nicolaus set a $31.00 price target on Envista in a report on Friday, February 6th. Wells Fargo & Company raised their price target on Envista from $21.00 to $26.00 and gave the company an “equal weight” rating in a report on Friday, February 6th. Finally, Morgan Stanley raised their price target on Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Friday. Seven research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Envista presently has an average rating of “Hold” and a consensus price target of $27.85.

Get Our Latest Stock Analysis on Envista

Insider Transactions at Envista In related news, SVP Mischa Reis sold 9,675 shares of Envista stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total transaction of $290,250.00. Following the transaction, the senior vice president directly owned 32,382 shares of the company’s stock, valued at $971,460. The trade was a 23.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.99% of the stock is currently owned by insiders.

Envista Price Performance NYSE:NVST opened at $26.84 on Friday. The business’s 50-day moving average price is $26.91 and its 200 day moving average price is $23.72. The firm has a market cap of $4.37 billion, a P/E ratio of 95.84, a PEG ratio of 1.85 and a beta of 0.98. Envista Holdings Corporation has a 52-week low of $15.49 and a 52-week high of $30.42. The company has a quick ratio of 2.04, a current ratio of 2.38 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST – Get Free Report) last released its earnings results on Thursday, February 5th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.The company’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, sell-side analysts predict that Envista Holdings Corporation will post 1.4 earnings per share for the current fiscal year.

Envista Profile (Free Report)

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.

Further Reading Five stocks we like better than Envista Want to see what other hedge funds are holding NVST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Envista Holdings Corporation (NYSE:NVST – Free Report).

Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEUnion Pacific (NYSE:UNP) Stock Price Expected to Rise, TD Cowen Analyst Says

NEXT HEADLINE »Vertiv (NYSE:VRT) Price Target Raised to $350.00

, /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended April 3, 2026.

"We delivered a good start to 2026, with first quarter results reflecting continued strong execution and progress in support of our strategic priorities," said Paul Keel, CEO. "We delivered growth across all our major businesses, driven by customer engagement and new product commercialization. Our 9.5% core revenue growth converted to 25% adjusted EBITDA and 50% EPS growth, while also supporting double-digit increases in R&D and Sales & Marketing investment. With momentum continuing, we are reaffirming our full-year guidance and announcing an incremental $300 million share repurchase program."

First Quarter Financial Highlights

Sales were $706 million, with core sales growth of 9.5% over the first quarter of 2025. GAAP diluted EPS of $0.23 and adjusted diluted EPS of $0.36 (+50% year-on-year) GAAP Net Income was $39 million and adjusted EBITDA was $99 million (+25% year-on-year), with an adjusted EBITDA margin of 14.0% (+120 bps year-on-year) First Quarter Business Highlights

Growth:  In the context of macro uncertainty, all major businesses delivered positive growth, with 8.4% core growth in our Specialty Products & Technologies segment and 11.5% core growth in our Equipment and Consumables segment. Operations:  Ongoing broad-based contributions from the Envista Business System (EBS) supporting 100 bps of Gross Margin and 120 bps of adjusted EBITDA margin expansion. People:  Continued gains in employee engagement and talent development; 3700 patients served through our charitable Envista Smile Project. Net Income, EBITDA, and EPS (in millions, except per share amounts):

Three Months Ended

April 3, 2026

March 28, 2025

GAAP Net Income

$                     39

$                     18

Adjusted Net Income

$                     60

$                     42

Adjusted EBITDA

$                     99

$                     79

GAAP Diluted Earnings Per Share

$                  0.23

$                  0.10

Adjusted Diluted Earnings Per Share                                                                 

$                  0.36

$                  0.24

Cash Flow:

Operating cash flow for the first quarter of 2026 was negative $3 million and free cash flow was negative $16 million, compared to $0 million and negative $5 million in the first quarter of 2025, respectively. 

Share Repurchases:

During the quarter ended April 3, 2026, we repurchased 1.6 million shares for approximately $43 million.  At the end of the quarter, we had approximately $41 million remaining repurchase capacity under our stock repurchase program.

On May 5, 2026, our Board of Directors authorized a new stock repurchase program under which we may repurchase an incremental $300 million of our outstanding common stock through December 31, 2029.

Outlook:

We are maintaining the following guidance for the full year 2026:

            2026 Guidance            

Core Sales Growth

2% to 4%

Adjusted EBITDA Growth

7% to 13%

Adjusted Diluted Earnings Per Share                                                                           

$1.35 to $1.45

Free Cash Conversion

~100%

Please note, we do not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.

We will discuss our quarterly results and provide details on our outlook for 2026 during an investor conference call on May 6, 2026, starting at 2:00 P.M. PT. The call and an accompanying slide presentation will be webcast on the "Investors" section of our website, www.envistaco.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of our website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 800-836-8184 within the U.S. or +1 646-357-8785 outside the U.S. a few minutes before 2:00 PM PT and referencing conference ID #51461.  A replay of the conference call will be available shortly after the conclusion of the call. You can access the replay dial-in information on the "Investors" section of our website under the subheading "Events & Presentations." Presentation materials relating to our results have been posted to the "Investors" section of our website under the subheading "Quarterly Earnings".

ABOUT ENVISTA

Envista is a global leader in the dental industry, uniting more than 30 trusted brands—including DEXIS, Kerr, Nobel Biocare, and Ormco—under one mission: partnering with dental professionals to improve patients' lives. With a heritage of category-defining innovation, our brands have shaped modern dentistry: Nobel Biocare introduced the first dental implant, Ormco is a pioneer in both traditional and digital orthodontics, DEXIS has long been at the forefront of 2D, 3D and intraoral imaging, and Kerr has supported clinicians for over 135 years.  Our high-performing culture is underpinned by our CIRCLe Values and the Envista Business System.  Guided by these, we deliver a comprehensive portfolio of technologies, consumables, and services that empower clinicians to provide confident, efficient care—today and for the future.  Learn more at http://envistaco.com.

NON-GAAP MEASURES

All "Adjusted" amounts including core sales growth and free cash flow are non-GAAP items. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these non-GAAP measures are included in the attached supplemental schedules. We do not reconcile forward looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation, acquisitions, discontinued products, and any other potential adjustments which would be reflected in any forecasted GAAP measure.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the conditions in the U.S. and global economy, the impact of inflation and increasing interest rates, slower economic growth or recession, international economic, political, legal, compliance and business factors, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations including tariffs or other impositions on imported goods, contractions or growth rates and cyclicality of markets we serve, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, disruptions relating to war (including supply chain disruptions), terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events, security breaches or other disruptions of our information technology systems or violations of data privacy laws, security breaches or other disruptions affecting our external information technology contractors, vendors or other service providers, our growing use of artificial intelligence systems to automate processes and analyze data, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, our ability to attract, develop and retain our key personnel, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to impairment charges for our goodwill and intangible assets, changes in accounting standards and subjective assumptions, estimates and judgment by management, currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, the impact of regulation on demand for our products and services, and labor matters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2025 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

CONTACT
Jim Gustafson
Vice President, Investor Relations
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
[email protected]

ENVISTA HOLDINGS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

($ and shares in millions, except per share amounts)

Three Months Ended

April 3, 2026

March 28, 2025

Sales

$            705.5

$            616.9

Cost of sales

315.4

280.9

Gross profit

390.1

336.0

Operating expenses:

Selling, general and administrative

297.6

271.7

Research and development

30.0

25.3

Operating profit

62.5

39.0

Nonoperating (expense) income:

Other expense, net

(2.9)

(0.7)

Interest expense, net

(7.4)

(9.3)

Income before income taxes

52.2

29.0

Income tax expense

13.5

11.0

Net income

$             38.7

$             18.0

Earnings per share:

Earnings - basic

$             0.24

$             0.10

Earnings - diluted

$             0.23

$             0.10

Average common stock and common equivalent shares outstanding:                                       

Basic

163.9

172.4

Diluted

166.4

173.6

ENVISTA HOLDINGS CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

($ in millions, except share amounts)

As of

April 3, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$           1,082.8

$         1,211.7

     Trade accounts receivable, less allowance for credit losses of $23.7 and $22.5,          

     respectively

436.6

429.6

Inventories, net

300.3

288.1

Prepaid expenses and other current assets

99.4

97.2

Total current assets

1,919.1

2,026.6

Property, plant and equipment, net

298.7

296.8

Operating lease right-of-use assets

143.6

142.1

Other long-term assets

223.8

228.1

Goodwill

2,359.8

2,358.2

Other intangible assets, net

633.0

627.2

Total assets

$           5,578.0

$         5,679.0

LIABILITIES AND EQUITY

Current liabilities:

Trade accounts payable

170.0

191.6

Accrued expenses and other liabilities

577.9

622.0

Operating lease liabilities

38.7

39.0

Total current liabilities

786.6

852.6

Operating lease liabilities

111.4

110.4

Other long-term liabilities

161.4

161.4

Long-term debt

1,439.1

1,448.3

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.01 par value, 15.0 million shares authorized; no shares issued

or outstanding at April 3, 2026 and December 31, 2025

—

—

Common stock, $0.01 par value, 500.0 million shares authorized; 176.2 million

shares issued and 162.9 million shares outstanding at April 3, 2026; 175.4 million

shares issued and 163.8 million shares outstanding at December 31, 2025

1.8

1.8

Treasury stock at cost; 13.3 million shares and 11.6 million shares at April 3, 2026

and December 31, 2025, respectively

(273.5)

(224.5)

Additional paid-in capital

3,896.0

3,882.6

Accumulated deficit

(401.7)

(440.4)

Accumulated other comprehensive loss

(143.1)

(113.2)

Total stockholders' equity

3,079.5

3,106.3

Total liabilities and stockholders' equity

$           5,578.0

$         5,679.0

ENVISTA HOLDINGS CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

($ in millions)

Three Months Ended

April 3, 2026

March 28, 2025

Cash flows from operating activities:

Net income

$              38.7

$               18.0

Noncash items:

Depreciation

10.4

9.1

Amortization

18.8

18.8

Allowance for credit losses

4.4

1.3

Stock-based compensation expense

10.2

7.1

Loss on investments in rabbi trust, net

0.9

0.6

Loss on equity investments

2.0

—

Loss on sale of property, plant and equipment

0.1

—

Restructuring charges

—

0.2

Non-cash operating lease costs

9.1

8.4

Amortization of debt discount and issuance costs

1.0

1.1

Change in trade accounts receivable

(13.3)

(21.3)

Change in inventories

(9.6)

(10.1)

Change in trade accounts payable

(21.4)

(15.1)

Change in prepaid expenses and other assets

(3.1)

(7.8)

Change in accrued expenses and other liabilities

(39.8)

0.8

Change in operating lease liabilities

(11.7)

(10.8)

Net cash (used in) provided by operating activities

(3.3)

0.3

Cash flows from investing activities:

Payments for additions to property, plant and equipment

(12.5)

(5.9)

Purchases of investments held in rabbi trust

(3.4)

(0.7)

Proceeds from sale of investments held in rabbi trust

0.5

0.7

Proceeds from sales of property, plant and equipment

0.1

0.5

Acquisitions, net of cash acquired

(54.4)

(3.6)

All other investing activities, net

0.8

0.2

Net cash used in investing activities

(68.9)

(8.8)

Cash flows from financing activities:

Proceeds from stock option exercises

3.5

0.8

Cash paid for treasury stock under the stock repurchase program

(42.7)

(14.6)

Treasury stock purchases related to tax withholding on equity awards                                  

(6.0)

(3.8)

All other financing activities

(0.4)

—

Net cash used in financing activities

(45.6)

(17.6)

Effect of exchange rate changes on cash and cash equivalents

(11.1)

34.3

Net change in cash and cash equivalents

(128.9)

8.2

Beginning balance of cash and cash equivalents

1,211.7

1,069.1

Ending balance of cash and cash equivalents

$           1,082.8

$           1,077.3

ENVISTA HOLDINGS CORPORATION

SUMMARY OF FINANCIAL METRICS (Unaudited)

($ in millions, except per share amounts)

GAAP

Three Months Ended

April 3, 2026

March 28, 2025

Gross Profit

$            390.1

$            336.0

Operating Profit

$              62.5

$              39.0

Net Income

$              38.7

$              18.0

Diluted Earnings Per Share                                                                                                           

$              0.23

$              0.10

Operating Cash Flow

$              (3.3)

$               0.3

NON-GAAP *

Three Months Ended

April 3, 2026

March 28, 2025

Adjusted Gross Profit

$             393.6

$            338.3

Adjusted Operating Profit

$              89.4

$              70.6

Adjusted Net Income

$              60.0

$              41.5

Adjusted Diluted EPS

$              0.36

$              0.24

Adjusted EBITDA

$              98.9

$              79.0

Free Cash Flow

$             (15.7)

$              (5.1)

* For information on non-GAAP measures see "Reconciliation of GAAP to Non-GAAP Financial Measures" below. Also see

  the accompanying "Notes to Reconciliation of GAAP to Non-GAAP Financial Measures."

ENVISTA HOLDINGS CORPORATION

SEGMENT INFORMATION (Unaudited)

($ in millions)

Three Months Ended

April 3, 2026

March 28, 2025

Sales

Specialty Products & Technologies                                                                                              

$            457.8

$            400.3

Equipment & Consumables

247.7

216.6

Total

$            705.5

$            616.9

Operating Profit (Loss)

Specialty Products & Technologies

$              46.5

$              37.6

Equipment & Consumables

46.8

31.9

Other

(30.8)

(30.5)

Total

$              62.5

$              39.0

Operating Margins

Specialty Products & Technologies

10.2 %

9.4 %

Equipment & Consumables

18.9 %

14.7 %

Total

8.9 %

6.3 %

ENVISTA HOLDINGS CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)

($ and shares in millions, except per share amounts)

Adjusted Gross Profit and Adjusted Gross Margin

Three Months Ended

April 3, 2026

March 28, 2025

Gross Profit

$         390.1

$         336.0

Restructuring costs and asset impairments A

3.1

1.9

Fair value adjustment of acquisition-related inventory B

0.4

0.4

Adjusted Gross Profit

$         393.6

338.3

Gross Margin (Gross Profit / Sales)

55.3 %

54.5 %

Adjusted Gross Margin (Adjusted Gross Profit / Sales)

55.8 %

54.8 %

Adjusted Operating Profit

Three Months Ended

April 3, 2026

March 28, 2025

Consolidated

Operating Profit

$           62.5

$           39.0

Amortization of acquisition-related and other intangible assets                                                 

18.8

18.8

Restructuring costs and asset impairments A

7.4

11.4

Fair value adjustment of acquisition-related inventory B

0.4

0.4

Litigation settlement C

—

0.8

Acquisition-related expenses D

0.3

0.2

Adjusted Operating Profit

$           89.4

$           70.6

Adjusted Operating Profit as a % of Sales

12.7 %

11.4 %

Specialty Products & Technologies

Operating Profit

$           46.5

$           37.6

Amortization of acquisition-related and other intangible assets

15.6

14.6

Restructuring costs and asset impairments A

4.4

4.2

Adjusted Operating Profit

$           66.5

$           56.4

Adjusted Operating Profit as a % of Sales

14.5 %

14.1 %

Equipment & Consumables

Operating Profit

$           46.8

$           31.9

Amortization of acquisition-related and other intangible assets

3.2

4.2

Restructuring costs and asset impairments A

2.0

2.3

Litigation settlement C

—

0.8

Adjusted Operating Profit

$           52.0

$           39.2

Adjusted Operating Profit as a % of Sales

21.0 %

18.1 %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

Adjusted Net Income

Three Months Ended

April 3, 2026

March 28, 2025

Net Income

$             38.7

$             18.0

Amortization of acquisition-related and other intangible assets

18.8

18.8

Restructuring costs and asset impairments A

7.4

11.4

Fair value adjustment of acquisition-related inventory B

0.4

0.4

Litigation settlement C

—

0.8

Acquisition-related expenses D

0.3

0.2

Loss on equity investments E

2.0

—

Tax effect of adjustments reflected above F

(7.8)

(8.8)

Discrete tax adjustments and other tax-related adjustments G

0.2

0.7

Adjusted Net Income

$             60.0

$             41.5

Adjusted Diluted Earnings Per Share

Three Months Ended

April 3, 2026

March 28, 2025

Diluted Earnings Per Share

$             0.23

$             0.10

Amortization of acquisition-related and other intangible assets

0.11

0.11

Restructuring costs and asset impairments A

0.05

0.07

Fair value adjustment of acquisition-related inventory B

—

—

Litigation settlement C

—

0.01

Acquisition-related expenses D

—

—

Loss on equity investments E

0.01

—

Tax effect of adjustments reflected above F

(0.04)

(0.05)

Discrete tax adjustments and other tax-related adjustments G

—

—

Adjusted Diluted Earnings Per Share

$             0.36

$             0.24

Adjusted EBITDA

Three Months Ended

April 3, 2026

March 28, 2025

Net Income

$           38.7

$          18.0

Interest expense, net

7.4

9.3

Income tax expense

13.5

11.0

Depreciation

10.4

9.1

Amortization of acquisition-related and other intangible assets

18.8

18.8

Restructuring costs and asset impairments A

7.4

11.4

Fair value adjustment of acquisition-related inventory B

0.4

0.4

Litigation settlement C

—

0.8

Acquisition-related expenses D

0.3

0.2

Loss on equity investments E

2.0

—

Adjusted EBITDA

$           98.9

$          79.0

Adjusted EBITDA as a % of Sales

14.0 %

12.8 %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

 Core Sales Growth 1

Consolidated

% Change Three Month

Period Ended April 3, 2026 vs.

Comparable 2025 Period

Total sales growth

14.4 %

Plus the impact of:

Acquisitions

(0.6) %

Currency exchange rates

(4.3) %

Core Sales Growth

9.5 %

Specialty Products & Technologies                                                                                                   

Total sales growth

14.4 %

Plus the impact of:

Acquisitions

(0.9) %

Currency exchange rates

(5.1) %

Core Sales Growth

8.4 %

Equipment & Consumables

Total sales growth

14.4 %

Plus the impact of:

Currency exchange rates

(2.9) %

Core Sales Growth

11.5 %

1   

We use the term "core sales" to refer to GAAP revenue excluding  (1) sales from acquired businesses recorded prior to the first

anniversary of the acquisition ("acquisitions"), (2) sales from discontinued products and (3) the impact of currency translation.

Sales from discontinued products includes major brands or products that Envista has made the decision to discontinue as part

of a portfolio restructuring. Discontinued brands or products consist of those which Envista (1) is no longer manufacturing, (2) is

no longer investing in the research or development of, and (3) expects to discontinue all significant sales within one year from

the decision date to discontinue. The portion of sales attributable to discontinued brands or products is calculated as the net

decline of the applicable discontinued brand or product from period-to-period. The portion of GAAP revenue attributable to

currency exchange rates is calculated as the difference between (a) the period-to-period change in sales and (b) the

period-to-period change in sales after applying current period foreign exchange rates to the prior year period. We use the term

"core sales growth" to refer to the measure of comparing current period core sales with the corresponding period of the prior year.

During the first quarter of 2026, we updated our methodology for how we calculate changes in the sales price from period to

period. Changes in sales prices are now calculated by comparing the current quarter sales prices to the full year sales price

average from the prior year as it better reflects pricing trends over time.

Reconciliation of Operating Cash Flows to Free Cash Flow

Three Months Ended

April 3, 2026

March 28, 2025

Net operating cash (used in) provided by operating activities

$           (3.3)

$            0.3

Less: payments for additions to property, plant and equipment (capital expenditures)                  

(12.5)

(5.9)

Plus: proceeds from sales of property, plant and equipment

0.1

0.5

Free Cash Flow (FCF)

$         (15.7)

$           (5.1)

FCF to Adjusted Net Income Conversion Ratio

(26.2) %

(12.3) %

See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

ENVISTA HOLDINGS CORPORATION
NOTES TO RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)

A We exclude impairment of certain long-lived assets, executive transition costs, and cost incurred pursuant to discrete restructuring plans. 

B Represents the fair value adjustment related to inventory acquired in connection with acquisitions.

C Represents the settlement of certain litigation matters.

D Represents acquisition-related transaction expenses and integration costs with respect to business combinations.

E Represents losses on equity investments.

F This line item represents the aggregate tax effect of all pretax adjustments reflected in the preceding line items of the table using each adjustment's applicable tax rate, including the effect of interim tax accounting requirements of Accounting Standards Codification Topic 740 Income Taxes.

G Discrete tax matters primarily relate to excess tax benefits from stock-based compensation, changes in estimates associated with prior period uncertain tax positions and audit settlements, tax benefits resulting from a change in law, and changes in determination of realization of certain deferred tax assets.

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Envista Holdings Corporation's ("Envista" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:

with respect to Core Sales, identify underlying growth trends in Envista's business and compare Envista's revenue performance with prior and future periods and to Envista's peers; with respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, understand the long-term profitability trends of Envista's business and compare Envista's profitability to prior and future periods and to Envista's peers; with respect to Adjusted EBITDA, help investors understand operational factors associated with Envista's financial performance because it excludes the following from consideration:  interest, taxes, depreciation, amortization, and infrequent or unusual losses or gains such as goodwill impairment charges or nonrecurring and restructuring charges. Management uses Adjusted EBITDA, as a supplemental measure for assessing operating performance in conjunction with related GAAP amounts.  In addition, Adjusted EBITDA is used in connection with operating decisions, strategic planning, annual budgeting, evaluating Company performance and comparing operating results with historical periods and with industry peer companies; and with respect to Free Cash Flow (the "FCF Measure"), understand Envista's ability to generate cash without external financings, in order to invest and grow its business through acquisitions and other strategic opportunities. A limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire Free Cash Flow amount is not necessarily available for discretionary expenditures. Management uses these non-GAAP measures to evaluate the Company's operating and financial performance.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

With respect to Adjusted Gross Profit, Adjusted Operating Profit, Adjusted Net Income, Adjusted Diluted Earnings Per Share and Adjusted EBITDA: We exclude amortization of acquisition-related and other intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition.  Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies.  We believe, however, that it is important for investors to understand that such intangible assets contribute to revenue generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. With respect to the other items excluded from Adjusted Gross Profit, Adjusted Net Income, Adjusted Operating Profit, Adjusted Diluted Earnings Per Share and Adjusted EBITDA, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Envista's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. With respect to core sales, we exclude (1) the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult, (2) sales from discontinued products because discontinued products do not have a continuing contribution to operations and management believes that excluding such items provides investors with a means of evaluating our on-going operations and facilitates comparisons to our peers, and (3) the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends. With respect to the FCF Measure, we adjust for payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to arrive at the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements. SOURCE Envista Holdings Corporation

For the quarter ended March 2026, Envista (NVST - Free Report) reported revenue of $705.5 million, up 14.4% over the same period last year. EPS came in at $0.36, compared to $0.24 in the year-ago quarter.

The reported revenue represents a surprise of +4.75% over the Zacks Consensus Estimate of $673.52 million. With the consensus EPS estimate being $0.31, the EPS surprise was +16.13%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Envista performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Geographic Sales- Equipment & Consumables- Other developed markets: $8.4 million versus $8.91 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.2% change.Geographic Sales- Equipment & Consumables- Emerging markets: $34 million compared to the $30.74 million average estimate based on three analysts. The reported number represents a change of +14.9% year over year.Geographic Sales- North America: $364.2 million versus the three-analyst average estimate of $353.73 million. The reported number represents a year-over-year change of +12.3%.Geographic Sales- Western Europe: $184.8 million versus the three-analyst average estimate of $156.12 million. The reported number represents a year-over-year change of +29%.Geographic Sales- Other developed markets: $31.5 million versus $32.45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.6% change.Geographic Sales- Equipment & Consumables- Western Europe: $30.5 million versus $26.73 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +20.6% change.Geographic Sales- Specialty Products & Technologies- North America: $189.4 million versus $186.87 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change.Geographic Sales- Specialty Products & Technologies- Western Europe: $154.3 million versus the three-analyst average estimate of $129.39 million. The reported number represents a year-over-year change of +30.8%.Geographic Sales- Specialty Products & Technologies- Other developed markets: $23.1 million versus the three-analyst average estimate of $23.54 million. The reported number represents a year-over-year change of +5.5%.Geographic Sales- Specialty Products & Technologies- Emerging markets: $91 million compared to the $98.98 million average estimate based on three analysts. The reported number represents a change of +2% year over year.Sales- Equipment & Consumables: $247.7 million versus $232.08 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +14.4% change.Sales- Specialty Products & Technologies: $457.8 million versus the four-analyst average estimate of $438.46 million. The reported number represents a year-over-year change of +14.4%.View all Key Company Metrics for Envista here>>>

Shares of Envista have returned +3.6% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

My existing 'buy' rating for Envista is left unchanged following my evaluation of its results and outlook. NVST's 1Q2026 earnings beat consensus by 15%, thanks to a defensive dental market and the company's own cost reduction efforts. The company's high-teens EPS growth guidance for the full year is well-supported by new product launches and synergies relating to its latest M&A.

Have you assessed how the international operations of Envista (NVST - Free Report) performed in the quarter ended March 2026? For this maker of dental products, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.

In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

Our review of NVST's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.

For the quarter, the company's total revenue amounted to $705.5 million, experiencing an increase of 14.4% year over year. Next, we'll explore the breakdown of NVST's international revenue to understand the importance of its overseas business operations.

Unveiling Trends in NVST's International RevenuesEmerging markets generated $125 million in revenues for the company in the last quarter, constituting 17.7% of the total. This represented a surprise of -3.64% compared to the $129.72 million projected by Wall Street analysts. Comparatively, in the previous quarter, Emerging markets accounted for $165 million (22%), and in the year-ago quarter, it contributed $118.8 million (19.3%) to the total revenue.

During the quarter, Other developed markets contributed $31.5 million in revenue, making up 4.5% of the total revenue. When compared to the consensus estimate of $32.45 million, this meant a surprise of -2.93%. Looking back, Other developed markets contributed $32 million, or 4.3%, in the previous quarter, and $30.4 million, or 4.9%, in the same quarter of the previous year.

Of the total revenue, $184.8 million came from Western Europe during the last fiscal quarter, accounting for 26.2%. This represented a surprise of +18.37% as analysts had expected the region to contribute $156.12 million to the total revenue. In comparison, the region contributed $178.8 million, or 23.8%, and $143.3 million, or 23.2%, to total revenue in the previous and year-ago quarters, respectively.

Revenue Forecasts for the International MarketsFor the current fiscal quarter, it is anticipated by Wall Street analysts that Envista will post revenues of $713.84 million, which reflects an increase of 4.7% the same quarter in the previous year. The revenue contributions are expected to be 22.4% from Emerging markets ($159.88 million), 4.3% from Other developed markets ($30.72 million) and 22.5% from Western Europe ($160.25 million).

For the full year, the company is expected to generate $2.86 billion in total revenue, up 5.1% from the previous year. Revenues from Emerging markets, Other developed markets and Western Europe are expected to constitute 22% ($627.34 million), 4.5% ($127.79 million) and 22% ($627.21 million) of the total, respectively.

In ConclusionEnvista's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

With the increasing intricacies of global interdependence and geopolitical strife, Wall Street analysts meticulously observe these patterns, especially for companies with an international footprint, to tweak their forecasts of earnings. Importantly, several additional factors, such as a company's domestic market status, also impact these earnings forecasts.

At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.

The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.

Currently, Envista holds a Zacks Rank #3 (Hold), signifying its potential to match the overall market's performance in the forthcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Reviewing Envista's Recent Stock Price TrendsThe stock has witnessed a decline of 8.2% over the past month versus the Zacks S&P 500 composite's an increase of 9.1%. In the same interval, the Zacks Medical sector, to which Envista belongs, has registered a decrease of 2.9%. Over the past three months, the company's shares saw a decrease of 16.3%, while the S&P 500 increased by 7.1%. In comparison, the sector experienced a decline of 9.8% during this timeframe.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Envista (NVST - Free Report) Headquartered in Brea, CA, Envista Holdings Corporation was formed in 2018 as a wholly-owned subsidiary of Danaher Corporation (“Danaher”) to serve as the ultimate parent company of the dental platform of Danaher. The company is built through the acquisition and integration of over 25 leading dental businesses and brands over 15 years.

NVST is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.74; value investors should take notice.

Four analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.02 to $1.43 per share. NVST also boasts an average earnings surprise of +15.4%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, NVST should be on investors' short list.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Envista (NVST - Free Report) Headquartered in Brea, CA, Envista Holdings Corporation was formed in 2018 as a wholly-owned subsidiary of Danaher Corporation (“Danaher”) to serve as the ultimate parent company of the dental platform of Danaher. The company is built through the acquisition and integration of over 25 leading dental businesses and brands over 15 years.

NVST is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 16.4; value investors should take notice.

For fiscal 2026, five analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $1.43 per share. NVST boasts an average earnings surprise of +15.4%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, NVST should be on investors' short list.

Key Takeaways Envista is up 5.7% YTD and 22.3% over a year while its sub-industry slumped. NVST Q1 2026 revenue rose 14.4% to $705.5M; adjusted EPS jumped 50% to $0.36. Envista kept 2026 core sales growth at 2%-4% and expects adj. EPS $1.35-$1.45. Envista Corporation (NVST - Free Report) has started to rebuild investor confidence, but the valuation question is still front and center. The stock trades at 15.1x forward 12-month earnings, a modest premium to its Zacks sub-industry at 14.9x, and a discount to the Zacks sector at 19.6x and the S&P 500 at 22.2x. 

Image Source: Zacks Investment Research

With shares at $22.94 and a $24 price target tied to a 16.2x forward 12-month earnings multiple, the setup is about whether recent execution can hold long enough to justify a slightly higher multiple. 

NVST Valuation Setup Using the Report’s MultiplesThe market is assigning Envista 15.1x forward 12-month earnings. That level sits close to the sub-industry’s 14.9x, implying investors are not yet paying up for a decisive re-rating. At the same time, the discount to the sector (19.6x) and the S&P 500 (22.2x) suggests expectations remain restrained. 

The $24 price target is anchored to a 16.2x forward 12-month earnings multiple, which is only modestly above today’s trading level. Put differently, the upside case is not dependent on a big multiple expansion. It depends on Envista sustaining the operating improvements now showing up in results.

Envista Price Performance Context and What It Can MisleadEnvista shares are up 5.7% year to date and up 22.3% over the past year. That performance looks more constructive when set against a weak peer backdrop: the Zacks sub-industry is down 25.2% year to date and down 30.9% over the past year, while the Zacks Medical sector is down 6.6% year to date and up 2.7% over the past year. 

Benchmark dispersion matters because multiples are forward-looking reflections of market expectations. A sub-industry drawdown can compress peer multiples even if fundamentals differ, while a more resilient sector line can keep sector-level valuations elevated. Against that backdrop, Envista’s near-sub-industry multiple reads less like “cheapness” and more like a market that wants proof the recent momentum is repeatable.

NVST Earnings Power: What Q1 2026 RevealedThe first quarter of 2026 showed meaningful profit acceleration alongside solid top-line growth. Revenue was $705.5 million, up 14.4% year over year. Adjusted diluted earnings per share were $0.36, up 50% year over year, while GAAP diluted earnings per share were $0.23. 

The quality of the improvement matters. Adjusted gross margin expanded 100 basis points to 55.8%, supported by volume, price, productivity and favorable foreign exchange. Operating expenses also grew more slowly than revenue, with selling, general and administrative expenses up 9.5% to $297.6 million, even as research and development spending rose 18.6% to $30.0 million. 

NVST 2026 Outlook: What Must Go RightManagement maintained its full-year 2026 outlook for core sales growth of 2% to 4%. The Zacks Consensus Estimate calls for $2.86 billion of revenue, implying 5.1% growth from the year-ago reported figure. That gap sets up a clear “meet the bar” framework: the market will watch whether reported results can track closer to consensus while still fitting inside the company’s core-sales lens.

Earnings expectations are similarly defined. Adjusted diluted earnings per share are expected to be between $1.35 and $1.45, while the Zacks Consensus Estimate is $1.43. With the stock priced off forward earnings, execution against that range is a key driver of whether the multiple holds.

Envista Rating Lens for Near-Term Decision MakersFor investors using a shorter time horizon, the Zacks Rank provides the primary signal. Envista currently carries a Zacks Rank #3 (Hold). The Style Scores show what the model is rewarding: VGM is B, with Value at B, Growth at C and Momentum at B. 

That mix fits the current setup. The Value and Momentum profile aligns with a stock that has improved and is not priced like a sector leader, while the weaker Growth score reflects the need for continued follow-through in demand, share gains and operating leverage.

Based on short-term price targets offered by 13 analysts, the average price target of $29.85 represents an increase of 30.12% from the last closing price.

Image Source: Zacks Investment Research

NVST Checklist: What Would Change the MultipleA practical catalyst list starts with tariffs. Tariff costs increased $11 million year over year in the first quarter, but were offset by supply chain, general and administrative, and pricing initiatives. Sustained offsetting through pricing and productivity is central to protecting margins as similar quarterly levels are anticipated through 2026. 

Next is adoption. Recent launches include the Nobel S Series in implants, the Spark clear aligner launch in Japan, and DEXIS software enhancements adding artificial intelligence-driven workflow and diagnostics tools. Progress in China implants is also key, with uncertainty tied to expected volume-based procurement timing that management expects to begin between the second and third quarters. 

What could break the thesis is straightforward: weaker-than-expected traction for new products and software, higher tariff drag that outpaces mitigation, or macro softness that slows dental utilization and purchasing cycles. 

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Key Takeaways Envista posted positive growth across major businesses, led by double-digit gains in developed markets.NVST expanded margins via EBS benefits, offsetting higher tariff costs with pricing and efficiency actions.NVST's Spark launched in Japan, while China policy uncertainty and FX swings remain key challenges. Envista Holdings Corporation’s (NVST - Free Report) ongoing international expansion is strengthening its presence across a broader range of markets, creating significant opportunities for long-term growth. Supported by the company’s strategic priorities and growth-focused initiatives, it is well positioned to capitalize on emerging opportunities and deliver solid operational and financial performance in the upcoming quarters. Yet, a dull macroeconomic scenario and competitive pressure raise concerns for Envista’s operations.

Over the past year, this Zacks Rank #3 (Hold) stock has gained 21.5%, outpacing the industry’s decline of 29%. The S&P 500 composite has grown 26.8% in the same time frame.

The leading optical retailer has a market capitalization of $4.08 billion. The company’s earnings yield of 6.1% is well ahead of the industry’s 3.1%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 15.4%.

Tailwinds for NVSTInternational Reach and Channel Expansion: Developed markets were the key growth engine in first-quarter 2026, with North America and Europe both delivering double-digit gains. Developing markets are growing in the high single digits, excluding softness in China tied to policy uncertainty. 

The Spark launch in Japan adds a new growth vector in a sizable aligner market where the company already has strong orthodontic relationships, creating a cross-sell opportunity into clear aligners. 

Management also highlighted continued progress with dental support organizations (DSOs) and clinician education initiatives as key drivers of deeper market penetration. Envista’s broad geographic footprint and extensive channel presence, combined with targeted investments in customer support and clinical training, position the company to continue gaining market share as conditions normalize across its end markets.

Progress With Strategic Priorities: Envista’s strategy is centered on three priorities: growth, operations and people. The company’s growth agenda is supported by four key pillars. In the first quarter of 2026, all major businesses delivered positive growth, with core revenue increasing 8.4% in the Specialty Products & Technologies segment and 11.5% in the Equipment & Consumables segment.

To sustain market-share gains, Envista has continued to invest in sales and marketing as well as research and development, with spending in both areas rising at a double-digit rate. New product introductions remain a key growth driver. Recent launches include the Nobel S Series implant system, the introduction of Spark clear aligners in Japan and enhancements to DEXIS software that incorporate AI-powered workflow and diagnostic capabilities.

The Envista Business System (“EBS”) continued to deliver broad-based operational benefits, supporting gross margin expansion of 100 basis points and adjusted EBITDA margin growth of 120 basis points. Tariff costs increased $11 million from the prior year but were offset by supply chain, G&A and pricing initiatives.

With respect to its third strategic priority, people, Envista continues to strengthen its culture of continuous improvement, supported by ongoing gains in employee engagement and talent development. The company also extended its social impact through the Envista Smile Project, serving approximately 3,700 patients.

Image Source: Zacks Investment Research

Concerns for NVSTMacro and Policy Headwinds: Management continues to flag global economic uncertainty alongside geopolitical volatility, which can weigh on dental utilization and purchasing cycles. China remains a source of uncertainty for the implants business as channel partners continue to adjust inventory levels ahead of the anticipated volume-based procurement (VBP) process, which management expects to begin between the second and third quarters.

Tariffs also remain a cost headwind. First-quarter 2026 adjusted EBITDA reflected an $11 million year-over-year increase in tariff costs, with similar quarterly levels anticipated through 2026. While first-quarter profitability improved, these external pressures could limit operating leverage and introduce variability across quarters.

Foreign Exchange and Global Exposure: Envista's international footprint is not only a growth asset but also a risk factor. In the first quarter of 2026, 52.7% of revenues came from customers outside the United States, exposing sales, margins, and cash flow to currency fluctuations and regional demand variability. 

While balance-sheet hedging has reduced quarter-to-quarter volatility compared with the prior year, foreign exchange movements continue to affect performance and can influence reported results. In addition, regional disruptions, including conflicts in the Middle East and evolving conditions in China, add complexity to planning and may at times offset strength in developed markets.

NVST Stock Estimate TrendThe Zacks Consensus Estimate for 2026 earnings per share (EPS) has moved north at $1.42 over the past 30 days.

The Zacks Consensus Estimate for 2026 revenues is pegged at $2.86 billion, suggesting a 5.2% increase from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) . 

Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.

GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Integra LifeSciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.

Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.

Opendoor Technologies Inc. (OPEN) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript

Key Takeaways OPEN's shares have dropped 22.3% YTD amid elevated mortgage rates and weaker housing demand.Opendoor's profitability goals depend on faster inventory turnover and stable contribution margins.OPEN is expanding Mortgage and Cash Now, More Later products, but both remain early stage. Shares of Opendoor Technologies Inc. (OPEN - Free Report) have plunged 22.3% in the year-to-date period, trailing the Zacks Internet – Software industry, the broader Zacks Computer and Technology sector and even the S&P 500. On Monday, the stock closed at $4.53, below its 52-week high of $10.87 but well above the 52-week low of 51 cents. The detailed share price performance is shown in the chart below.

OPEN Stock Underperforms the Industry & the Market
Image Source: Zacks Investment Research

The company operates in a difficult housing environment marked by elevated mortgage rates, weaker affordability and softer housing demand. Although the company is seeing operational improvement under the Opendoor 2.0 model, the path toward profitability still depends on sustaining faster inventory turnover, stronger contribution margins and continued acquisition growth in a volatile market. Despite recent operational progress, elevated housing-market risks and an unproven long-term profitability profile raise concerns, making OPEN stock a risky bet for now. Here’s why it may be prudent for investors to sell the stock.

Elevated Mortgage Rates Pressure Opendoor’s Demand TrendsOpendoor faces pressure from elevated mortgage rates and weaker affordability conditions across the housing market. Management stated that mortgage rates remain “far too high,” while housing listings stay elevated, creating a difficult environment for housing demand and resale activity.

The difficult macro backdrop creates ongoing risk for OPEN’s resale margins and inventory performance. Higher mortgage rates reduce affordability for homebuyers, which can slow transaction activity and increase the risk of longer holding periods. Although resale velocity has improved under Opendoor 2.0, sustained weakness in housing demand could pressure acquisition economics and profitability targets.

OPEN’s Profitability Targets Rely on Consistent ExecutionOpendoor targets adjusted net income profitability on a forward 12-month basis by the end of 2026, but management also indicated that it still has “a lot left to prove.” The company stated that proof of the new operating model will require “more time, more reps, more shifts,” suggesting that recent improvements are still at an early stage.

The profitability outlook also depends on maintaining strong acquisition growth, faster resale velocity and stable contribution margins simultaneously. Management identified several metrics that could signal operational weakness, including slower acquisition growth, weaker cohort margins and rising inventory aging. Any deterioration across these areas could place additional pressure on profitability expectations over the coming quarters.

Opendoor’s New Growth Products Remain Early StageThe company is expanding products such as Opendoor Mortgage and Cash Now, More Later, but both initiatives remain early-stage businesses. Management stated that the company does not yet fully understand how the mortgage platform will perform across varying market conditions and home-price categories. Opendoor also keeps adjusting the Cash Now, More Later product to balance customer economics and platform profitability.

These offerings are expected to support platform growth and customer expansion, but execution risks remain elevated while the products evolve. If customer adoption weakens, margins deteriorate or operational complexity increases, these initiatives may not generate the expected long-term financial benefits.

Seasonal Housing Trends Could Pressure OPEN’s MarginsSeasonality remains an important risk factor for Opendoor’s operating performance. Management stated that days on market typically increase during the second half of the year, while margins generally compress during the fourth quarter. Acquisition activity is also adjusted around seasonal resale demand trends.

The seasonal slowdown creates additional inventory and pricing risk for the business. Longer resale cycles can increase holding costs, reduce pricing flexibility and pressure contribution margins. Although inventory health improved during the quarter, maintaining faster turnover rates may become more difficult if housing demand weakens further or market conditions deteriorate.

Competitive Landscape of OpendoorThe recent decline in Opendoor stock also needs to be assessed alongside how key peers are navigating the same housing and technology environment. Zillow Group (Z - Free Report) remains a major industry force and continues to influence digital real estate activity through large consumer traffic and the Premier Agent network. Although it stepped away from the iBuying model, Zillow Group still plays a key role in shaping online home search and data-driven discovery. This dynamic continues to push Opendoor to stand out through faster transactions and technology-based pricing models.

Offerpad Solutions Inc. (OPAD - Free Report) remains another direct participant in the iBuying space. The company operates with a more focused and localized strategy compared with Opendoor’s broader national scale. Offerpad Solutions has also been concentrating on improving pricing spreads and maintaining tighter operational control. These efforts reflect a broader industry focus on efficiency and disciplined growth as companies adjust to changing housing conditions.

OPEN Stock’s ValuationFrom a valuation standpoint, OPEN trades at a forward price-to-sales (P/S) multiple of 0.84, significantly below the industry’s average of 3.79. Conversely, industry players, such as Zillow Group and Offerpad Solutions, have P/S multiples of 2.66 and 0.08, respectively.

Image Source: Zacks Investment Research

Earnings Estimate Revision of OPENThe Zacks Consensus Estimate for OPEN’s 2026 earnings implies a year-over-year uptick of 53.9%. Loss per share estimates for 2026 have remained unchanged in the past 60 days.

Image Source: Zacks Investment Research

Conclusion: Sell Opendoor Stock for NowThe company is making operational improvements under its Opendoor 2.0 strategy, particularly in inventory management, resale velocity and acquisition growth. However, the business still operates in a highly uncertain housing environment where elevated mortgage rates, affordability pressure and seasonal demand swings continue to create risks for margins and long-term profitability. At the same time, several newer growth initiatives remain in the early stages and still need to prove scalability across different market conditions.

The company’s turnaround strategy also remains heavily dependent on flawless execution. Any slowdown in acquisition growth, deterioration in inventory turnover or renewed margin pressure could weigh on financial performance and investor sentiment. It is prudent for investors to exit investment from this Zacks Rank #4 (Sell) stock for now and consider re-evaluating once the margin trajectory stabilizes, as the company still needs to demonstrate more consistent profitability and sustained margin improvement.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- NavigateAI today officially launches with $25mm in funding to build AI copilots for field workers. Aiming to drastically improve how physical spaces are built and maintained, launch partners include Lennar, Roofstock, and Tishman Speyer. The $25mm seed round was led by Elad Gil with participation from Khosla Ventures, Lennar, Tishman Speyer, and Helix Electric alongside angels including Zach Frankel (Ramp), Dallas Tanner (Invitation Homes), Winston Weinberg (Harvey.ai), Jesse Zhang (Decagon), Tony Xu (DoorDash), and others.

The Mission

NavigateAI is building the trusted AI copilot for the physical world. NavigateAI puts an AI partner in the hands of every worker in the field, providing real-time upskilling, automating quality control, and helping teams build faster and cheaper.

A Builder Shortage That’s Compounding

In the US alone, $2.2T is spent annually on construction projects. Unfortunately, America has a shortage of hundreds of thousands of construction workers every year just to meet demand, and both the labor and skill gaps are accelerating. Alongside an aging population of workers, this is critical to address for four reasons:

Data centers. In our race for the most advanced AGI, we need faster data center construction.Housing. We have an affordability issue in housing, driven by high construction costs.The grid. The grid needs to be rebuilt to handle the demand from EVs, AI compute, and electrification.Reshoring. Reshoring manufacturing has created a surge of unplanned labor demand. Field Copilots

NavigateAI is building a field-grade copilot for the labor market that powers how things get built, maintained, and delivered. Specifically, we are building an AI-native system that operates as an expert coach for every field worker that can improve speed, cost, and quality at the same time. The AI copilots enable:

AI Upskilling and Coaching. Provides real-time guidance from a copilot that operates as an expert and craftsman in each category.AI Project Scoping. Produces a complete scope of work, materials list, and cost estimate, driven by expertise and intelligence.AI Quality Control. Enables real-time quality control against code, spec, and the original scope, catching defects at the point of work rather than at final inspection.AI Knowledge On-Demand. Query codes, spec sheets, manufacturer manuals, and a company’s own playbooks in the field, with answers in seconds. Product Experience

NavigateAI runs in real time on any phone with a camera, giving field workers a second set of expert eyes. Through a partnership with Meta, the experience goes hands-free on Meta Glasses, where the copilot sees exactly what the worker sees. Field workers build and install while AI supports, instructs, and verifies their work.

“We have a generational opportunity to upskill millions of workers with AI at the exact moment the country needs to build more and faster,” says Eric Wu, founder and CEO. “We're building the AI copilot that will enable this workforce transition.”

Launch Partners

NavigateAI is deploying with design partners across asset management, homebuilding, commercial construction, and data center construction including:

Lennar - Leader in homebuildingRoofstock - Leader in property managementAIM - Large electrical trade schoolTishman Speyer - Leader in commercial real estate “The partnership between Lennar and NavigateAI is designed to put modern technology shoulder to shoulder with our talented Trade Partners as we build the homes America needs with the high quality America expects,” says Stuart Miller, CEO of Lennar Corporation. “NavigateAI puts a quality-first AI copilot together with our workforce in the field, in order to raise the bar on quality for every family who moves into a Lennar home.”

The Team & Investors

NavigateAI is based in San Francisco with the founding team including builders and researchers from Opendoor, Stripe, DeepMind, Stanford, and Google. Eric Wu is the CEO and co-founder, who previously built and took public Opendoor (NASDAQ: OPEN), an online platform for buying and selling homes.

NavigateAI has raised $25mm in seed funding from investors across both venture capital and real estate.

Investors: Elad Gil, Khosla Ventures, Fifth WallStrategics: Lennar, Tishman Speyer, Helix ElectricAngels: Zach Frankel (Ramp), Dallas Tanner (Invitation Homes), Marcus Ridgway (Invitation Homes), Winston Weinberg (Harvey.ai), Gary Beasley (Roofstock), Jesse Zhang (Decagon), Apoorva Mehta (Instacart), Tony Xu (DoorDash), Logan Green (Lyft), Brian Armstrong, and more.
“Eric is one of the best founders I've backed multiple times now going after one of the biggest unsolved problems in the economy,” says Elad Gil, lead investor. “AI copilots for the physical world is the kind of application that will define the next era of AI.”

Looking Ahead

NavigateAI is building toward a future where every person who works in the physical world has an expert AI copilot. This capability is fundamental to expanding the skilled workforce at the pace the US now requires.

About NavigateAI

NavigateAI is building the AI copilot for the physical world. Founded in 2025, the company partners with leading owners, operators, builders, and trades teams to bring field-grade AI to the workers who build and maintain real assets. NavigateAI is based in San Francisco. Learn more at navigate.ai.

Media contact: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5a63f37f-8512-41c0-b418-e19c308259e4

Opendoor Technologies Inc. is in the early stages of a challenging turnaround, with fundamentals and stock price both trending sideways. Revenue continues to decline, but OPEN management is positive about the future and ramping up property acquisitions, signaling a potential inflection point. OPEN trades at just 1.1x TTM revenue and 4.2x TTM unlevered pretax FCF, making it attractive if growth resumes.

Key Takeaways OPEN's Opendoor Mortgage is live in Colorado, with early attach rates running ahead of expectations.OPEN says its rates run about 100 bps below market, enabled by fewer legacy systems and lower costs.OPEN is pursuing licensing in just over 20 states and expects to roughly double that footprint by Q3 end. Opendoor Technologies Inc. (OPEN - Free Report) is testing mortgages as a potential conversion lever within its broader housing platform. Opendoor Mortgage is currently live in Colorado, with early attach rates running ahead of expectations. The product adds a buyer-side financing layer to OPEN’s platform at a time when elevated borrowing costs continue to pressure affordability and housing transaction activity.

The initiative is built on an AI-native mortgage platform designed to streamline processing and reduce the cost structure relative to traditional lending models. OPEN stated that its mortgage rates are currently running about 100 basis points below the market average, supported by fewer legacy systems and lower reliance on commission-driven sales infrastructure.

Mortgage also aligns with Opendoor’s broader focus on reducing transaction friction. The company has rebuilt parts of its buyer apps, messaging systems and offer pages, while also introducing tools aimed at improving the home transaction process.

For OPEN, the mortgage model’s value will likely depend on whether the lower-rate structure can support sustained buyer conversion as availability expands. The company is pursuing licensing in just over 20 states and expects to roughly double that footprint by the end of the third quarter.

Mortgage adoption will likely become an important metric to watch as OPEN expands beyond Colorado. If lower rates help improve buyer conversion, the product could reduce purchase friction and strengthen Opendoor’s buyer-side platform. However, the opportunity remains early, and evidence that attach rates can hold across more markets will be important before mortgages become a meaningful part of OPEN’s turnaround case.

Peer Comparisons: Zillow & OfferpadZillow Group, Inc. (ZG - Free Report) provides a relevant benchmark for OPEN because its mortgage business is already more developed within a broader housing platform. In the first quarter of 2026, Zillow’s mortgage revenues increased 56% year over year, while purchase loan origination volume rose 96% to a record $1.5 billion. Zillow also reported 4.3 million users enrolled in its Buyability tool, underscoring the role of affordability insights in identifying higher-intent buyers earlier in the purchase process.

Offerpad Solutions Inc. (OPAD - Free Report) provides a closer comparison on transaction conversion, although it does not offer the same mortgage-led benchmark as Zillow. Offerpad is using Cash Offer, Cash Offer Marketplace, Brokerage Services and Renovate to retain more sellers within its platform. Its AI tools, SCOUT and HENRY, are designed to improve seller routing, acquisition accuracy, renovation estimates and disposition decisions.

Against this backdrop, OPEN’s competitive position depends on execution. Zillow reflects a more mature mortgage-integrated platform, while Offerpad highlights the role of multiple home-selling channels in improving conversion. For OPEN, sustained attach rates beyond Colorado would strengthen the case for its lower-rate mortgage model as a buyer-conversion lever as the rollout expands.

OPEN’s Stock Price Performance, Valuation & EstimatesShares of Opendoor have skyrocketed 677.4% in the past year against the industry’s 11.4% decline.

OPEN One-Year Price Performance
Image Source: Zacks Investment Research

From a valuation standpoint, OPEN trades at a forward price-to-sales (P/S) multiple of 0.93, significantly below the industry’s average of 3.83.

OPEN’s P/S Ratio (Forward 12-Month) vs. Industry
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for OPEN’s 2026 earnings implies a year-over-year uptick of 53.9%. Loss per share estimates for 2026 have remained unchanged in the past 60 days.

EPS Trend of OPEN Stock
Image Source: Zacks Investment Research

OPEN stock currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Change

(

-1.01

%) $

-0.04

Current Price

$

4.42

Opendoor Technologies (OPEN 1.01%), a digital home-selling platform, closed Tuesday at $5.41, up 1.88%. The stock moved higher as investors responded to news about its upcoming inclusion in the Russell 3000 index and are watching how index-driven inflows offset housing-market headwinds and ongoing losses.

The company’s trading volume reached 56.4 million shares, which is about 51% above compared with its three-month average of 37.4 million shares.

How the markets moved todayThe S&P 500 (^GSPC +0.37%) inched up 0.13% to 7,609.78, while the Nasdaq Composite (^IXIC +0.17%) added 0.03% to finish at 27,094. Within real estate services, industry peers Zillow Group (Z 0.34%) closed at $36.37 (up 0.33%) and Offerpad Solutions (OPAD 3.18%) ended at $0.82 (down 1.20%), highlighting mixed sentiment across housing-related platforms.

What this means for investorsOpendoor Technologies shares rose after the company announced it will join the Russell 3000 Index following the market close on June 26, which serves as a near-term catalyst. While inclusion may drive index-related buying and increased trading activity, it does not alter the operational challenges facing the digital real estate platform amid a challenging housing market.

Opendoor reported first-quarter revenue of $720 million, which was higher than expected even though sales dropped 37.6% from last year. Adjusted EBITDA was still negative at $31 million. Investors will be watching to see if the company can break even on adjusted EBITDA in the second quarter and show enough home resales to back up its software and AI-focused turnaround plan.

Eric Trie has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zillow Group. The Motley Fool has a disclosure policy.

© Pla2na / Shutterstock.com

Opendoor Technologies (NASDAQ:OPEN) is once again lighting up retail trading screens after a 588.38% one-year run that has turned a former penny stock into the housing trade of choice on r/wallstreetbets.

The iBuyer Math No Longer Works High borrowing costs are freezing residential transaction volume, and the low-margin iBuying model cannot survive a stalled housing market. The economics simply do not work when mortgage rates choke off turnover. Opendoor’s Q1 2026 revenue collapsed 38% year over year to $720 million, the GAAP net loss widened to $173 million from $85 million, and operating cash flow ran at negative $246 million. Full-year 2025 closed with a $1.3 billion net loss. Stock-based compensation surged to $120 million in the quarter, including $105 million in market-condition RSUs for the new CEO, even as shareholders absorbed the bleeding.

Management’s stated bull case is adjusted net income breakeven by the end of 2026. That is the goal: adjusted breakeven, well short of GAAP profitability. The stock trades at a forward P/E of 40x on earnings that do not yet exist, with a beta of 3.656 and zero dividend. Shares are down 22.3% year to date and Reddit sentiment flipped to “very bearish” on May 18, 2026. The crowd is finally noticing what the income statement has been screaming.

The Real Estate Monopoly Hiding in Plain Sight W. P. Carey (NYSE:WPC | WPC Price Prediction) is one of the largest diversified net-lease REITs in the world, and the structure of its business is the closest thing to a toll road that public equity markets offer retirement investors.

1. Triple-net leases shift every cost to the tenant. Corporate tenants pay all property maintenance, taxes, and insurance, leaving W. P. Carey to collect rent. The portfolio runs at 97.0% occupancy with a 12.1-year weighted-average lease term across more than 1,600 industrial, warehouse, and retail properties in the U.S. and Europe.

2. Inflation is built into the contracts. 48% of annualized base rent is linked to CPI escalators, with another 47% carrying fixed annual increases. Contractual same-store rent growth came in at 2.4%, and CEO Jason Fox told investors the company expects to “maintain an internal growth rate that’s among the best in the net lease sector.”

3. The dividend grows every quarter. The most recent payout climbed to $0.93 per share, paid April 15, 2026, the fifth consecutive quarterly increase. The annualized rate of $3.68 represents a 4.5% year-over-year hike, supporting a current yield near 4.89%. 2026 AFFO guidance of $5.13 to $5.23 per share implies low-to-mid 4% growth on top of an already-covered payout.

The stock has returned 17.31% year to date and 30.74% over the past year, with a beta of 0.783. Retirement capital benefits from predictable, contractual, inflation-protected cash flow from tenants legally obligated to pay.

WPC offers contractual, inflation-linked cash flow that the OPEN trade structurally cannot.

Key Takeaways Opendoor is using automation and AI workflows under Opendoor 2.0 to support cost discipline.Opendoor said an AI repair-negotiation tool reduced buyer fall-through rates by double digits in Q1 2026.Opendoor said AI scoping cut pre-list renovation spend by 10 to 20 percent per home in pilot markets. Opendoor Technologies Inc. (OPEN - Free Report) is using automation and AI-enabled tools to support cost control under its Opendoor 2.0 framework. The company is focused on improving operating accuracy, reducing friction and maintaining expense discipline as contract volumes recover in a weak housing market.

In the first quarter of 2026, OPEN highlighted early efficiency gains across several operating areas. The company cited an AI-powered repair negotiation tool that reduced buyer fall-through rates by double digits. It also noted that AI scoping feedback helped lower pre-list renovation spend by 10-20% per home in pilot markets, while ticket-triage automation allowed three full-time employees to shift from classification work to resolution activity.

OPEN’s model remains sensitive to execution costs, resale timing and inventory quality. Lower renovation spend, fewer failed buyer transactions and faster internal processes can reduce operational leakage across the resale cycle. Fixed operating expenses were $33 million in the first quarter, down 15.4% year over year, further supporting the company’s cost-discipline efforts.

AI also supports OPEN’s broader effort to accelerate home turns. The company has rebuilt parts of its buyer apps, messaging systems and offer pages while using automation to improve inspection, repair and operational execution. Greater efficiency can support faster resale cadence and better inventory discipline — both of which are important to protecting contribution margins in a pressured housing market.

Automation’s margin contribution will likely depend on whether these early use cases can scale as acquisition volumes increase. If AI-enabled tools continue to reduce renovation costs, limit transaction fall-through and improve operating productivity, they could become a more durable support for OPEN’s contribution margins under Opendoor 2.0.

Opendoor’s Competitor LandscapeZillow Group, Inc. (ZG - Free Report) provides a relevant benchmark for AI-led operating efficiency, although its model is less exposed to inventory ownership and resale-cost risk than OPEN’s. Zillow is embedding AI across consumer search, agent workflows, loan officer tools and rentals, while also noting that engineers are shipping 40% more code per engineer at the same or higher quality. This highlights how AI can improve productivity across a housing platform, even though Zillow’s margin profile is less tied to renovation costs, resale timing and home-level execution.

Offerpad Solutions Inc. (OPAD - Free Report) provides a closer comparison for OPEN’s margin-focused AI opportunity. Offerpad is using SCOUT to improve seller intake, routing and acquisition accuracy, while HENRY is being expanded to support renovation estimates, listing prices, holding-time decisions and disposition strategy. The company also said cost per qualified lead declined 37% year over year, underscoring the role of AI-enabled workflows in improving conversion efficiency and cost discipline in a weak housing market.

Against this backdrop, OPEN’s AI strategy will be most relevant if it improves the economics of the resale process. Zillow shows how AI can support platform productivity at scale, while Offerpad highlights the use of AI in seller routing, renovation and asset-level decisions. For OPEN, automation’s contribution-margin impact will depend on whether it can consistently reduce repair costs, limit transaction leakage and improve operating productivity as acquisition volumes recover.

OPEN’s Stock Price Performance, Valuation & EstimatesShares of Opendoor have skyrocketed 680.5% in the past year against the industry’s 16.4% decline.

OPEN One-Year Price Performance
Image Source: Zacks Investment Research

From a valuation standpoint, OPEN trades at a forward price-to-sales (P/S) multiple of 0.80, significantly below the industry’s average of 3.80.

OPEN’s P/S Ratio (Forward 12-Month) vs. Industry
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for OPEN's 2026 loss per share suggests a 61.5% year-over-year improvement. Loss per share estimates for 2026 have narrowed in the past 30 days.

EPS Trend of OPEN Stock
Image Source: Zacks Investment Research

Opendoor, the San Francisco-based online home-buying platform, is shutting down its India operations less than two years after expanding its presence in the country. The decision has become a flashpoint in the debate over whether AI is starting to alter the economics of offshore work.

In announcing the decision on Wednesday, CEO Kaz Nejatian cited a push to bring operational work back to the U.S., where Opendoor’s customers are, and a shift toward smaller AI-native teams. The company did not respond to requests for comment on how many employees were affected or how much of the decision was driven by AI efficiency. But the announcement quickly gained traction across Silicon Valley, where founders, investors, and outsourcing experts see it as an early example of how AI is reshaping the economics that made India a global hub for back-office operations.

To understand why they care, it helps to know what’s at stake for India. It has evolved far beyond its roots as a destination for outsourced back-office work. The country is now the world’s largest Global Capability Center market — a term for dedicated offshore units multinationals set up to handle everything from IT and finance to R&D — with more than 2,100 centers employing about 2.36 million people and generating nearly $100 billion in annual revenue.

Opendoor had built a large team in India to handle manual workflows across fragmented systems, Nejatian said. The company had nearly 250 employees in India when it opened offices in Chennai and Bengaluru in 2024. But the entire company has been scaling back in recent years. Securities filings show Opendoor employed 1,042 people globally at the end of last year, compared with 1,470 a year earlier. Similarly, its non-U.S. workforce declined to 184 employees at the end of last year, compared with 342 employees at the end of 2024.

Those broader workforce reductions make it difficult to view the India closure solely through the lens of outsourcing. Opendoor has been cutting costs across the business after a difficult period for the U.S. housing market that hit online home-buying companies especially hard. Still, the language Nejatian used to explain the move resonated with investors and outsourcing analysts who see AI reshaping how companies organize operational work.

Some investors viewed the decision as a sign of what AI could mean for India’s vast outsourcing workforce. “As manual work gets replaced by AI, a lot of jobs will be lost in India,” wrote Sheel Mohnot, co-founder of Better Tomorrow Ventures.

Others viewed Opendoor as evidence of a larger shift in how companies are organized. Keshav Lohia, a venture capitalist at Emergent Ventures, described the decision as a “watershed moment” for AI-driven operations, arguing that advances in AI are beginning to challenge the cost-arbitrage model that made India a popular offshoring destination.

Phil Fersht, chief executive of HFS Research, an advisory firm that tracks the global outsourcing and business services industry, told TechCrunch that the development should not be viewed simply as jobs moving from India to the U.S. The more important shift, he said, is that AI is reducing the amount of operational labor companies require in the first place, allowing firms to run leaner organizations regardless of location.

“This is not an isolated restructuring,” Fersht said. “It is part of a much broader pattern we are starting to see as companies redesign operations around AI, automation, and much leaner workflows.”

Fersht argued that the winners would be companies that combine AI, software, and human expertise to deliver outcomes without continually adding headcount, a model he described as “services-as-software.” While Opendoor may be one of the first high-profile examples, he said it is unlikely to be the last.

Some investors are already extrapolating beyond individual companies. Varun Rekhi, a venture capitalist at Speedinvest, argued that if AI reduces demand for labor-intensive services, it could eventually pressure one of India’s most important export industries, which is built around supplying talent and expertise to global corporations.

For now, Opendoor remains a complicated case study — a company that has been cutting headcount broadly for years, and whose India exit may say as much about its own struggles as it does about the future of AI and offshore work.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Jagmeet covers startups, tech policy-related updates, and all other major tech-centric developments from India for TechCrunch. He previously worked as a principal correspondent at NDTV.

You can contact or verify outreach from Jagmeet by emailing [email protected].

MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati.

On April 17, 2026, Bruker Corp (BRKR) shares rose 4.5% today, bringing the current price to $40.70. The stock has experienced a 52-week range of $28.53 to $56.2

A few weeks ago, a research paper out of MIT (the college) crossed my desk that most investors would have ignored.

It was about worms.

Specifically, it was about a team that had successfully mapped the entire brain of a microscopic worm — every neuron, every connection. 

Then it laid out what it would take to scale that process from a worm… to a mouse… and eventually, to a human.

Now, here’s where things get interesting for us.

For decades, mapping the human brain has been one of science’s biggest challenges. And while we’re still years away from a definitive solution, we’re starting to see the missing piece fall into place that could break the whole field wide open: brain-computer interfaces.

These are systems that allow the brain to communicate directly with machines — turning thought into action and speech.

Right now, the headlines focus on major players like Elon Musk’s Neuralink— buffeted by twelve patients, a $9B valuation, and IPO rumors.

Sam Altman also committed $250 million to his own brain-chip startup earlier this year.

The reporting surrounding these companies often leans toward the dramatic: the merging of mind and machine, the next frontier of artificial intelligence, the possibility of restoring lost functions or even augmenting human cognition. 

It is a story that lends itself to headlines. But it is also, in some ways, a misleading one. The visible pieces of this emerging field — the implants, the interfaces — represent only its final layer.

What they’re hiding is a much larger system that must exist before they can function in any meaningful way.

This is where the real opportunity lies for us. And in order to understand, we need to dig deeper than the headlines…

The Critical Systems Holding This Breakthrough Back Once I got over my initial excitement after reading the report and considering what it might mean, I did what traders do: I moved straight to the supply chain. 

The MIT thesis, perhaps unintentionally, offers a map of this growing system. 

It identifies several areas that must advance together: structural imaging, which captures the physical wiring of the brain; functional imaging, which records activity; molecular analysis, which explains how neurons behave; and computational infrastructure, which integrates and simulates these layers. 

Each of these parts has made significant progress in isolation. What’s new is the recognition that they are dependent on each other so that major progress in one without the others is unlikely.

This interdependence means that what we’re really looking at is a set of bottlenecks that are overlooked in the broader narrative.

This is exactly the kind of shift we focus on inside the Masters in Trading Challenge — learning how to move past the obvious story and identify where the real edge sits before it becomes consensus.

It’s not about predicting the headline outcome. It’s about understanding what has to happen underneath it—and positioning early. If you want to see exactly how we approach setups like this, you can learn more about the Masters in Trading Challenge here.

One of the clearest examples of this shows up in imaging. Imaging a brain at sufficient resolution is not simply a matter of improving a single machine. It requires scaling entire systems — microscopes, data pipelines, processing algorithms — by orders of magnitude.

The thesis suggests that even mapping a mouse brain would require dozens of high-throughput electron microscopes operating continuously for years.

And for a human brain? That demands far more extensive infrastructure that’s currently lacking.

The Next “Genome Project” Is Already Taking Shape Building these systems are not incremental challenges. They resemble, in scale and coordination, the kinds of efforts more commonly associated with large public works or scientific “moonshots.” 

The Human Genome Project – the effort to map all human DNA that turned biology into a data-driven science and made genetic research dramatically faster and cheaper – is often cited as an analogy. 

When it was all said and done, that project required more than a decade and billions of dollars to complete. 

Brain emulation, if pursued at a similar scale, would likely demand comparable levels of investment and collaboration.

If the history of technological change offers any guidance, it is that the most transformative shifts rarely occur where attention is first directed. 

They unfold, instead, in the spaces beneath the surface, where small advances accumulate until they alter what is possible.

The sensors. The chips. The imaging systems.

That’s where capital is starting to flow.

Right now, I’m tracking 14 names tied to this theme — 10 public, 4 private.

In today’s essay, I’m breaking down all fourteen names across three buckets:

Two to start with today Eight to build deeper exposure And four private companies to watch as they approach public markets. Let’s dive in…

Bucket 1 – Start Here If you only buy two names from this basket, start here.

Butterfly Network (BFLY): ~$500M market cap BFLY produces handheld, chip-based ultrasound devices used in brain imaging. And unlike some of the other names on this list, this early-stage player is already bringing in sound business.

Last quarter, BFLY turned profitable for the first time, with revenue growing 41% year-over-year to $31.5M.

That momentum is only increasing as BFLY secures more contracts around its signature tech. Its ultrasound chip is licensed into Forest Neurotech, an Eric Schmidt-backed brain-computer interface project – and that’s just one key partnership among many.

At a $500M market cap – with real revenue and BCI exposure – the risk/reward looks cleaner than most.

How I’d Play It Start a position and add on pullbacks to support. This isn’t a moonshot—it’s a functioning business with an underappreciated catalyst.

Quantum-Si (QSI): ~$194M market cap This is the asymmetric bet. It offers the only commercial single-molecule protein sequencer currently available on the market.

The MIT research identifies protein sequencing as a gating technology for brain mapping. Right now, this is the only U.S.-listed way to access it. With revenue at just $2.4 million, this is a company firmly in its earliest stages with massive growth ahead.

How I’d Play It Keep position size small. Treat it like a call option, not a core holding. If the thesis works, the upside could be significant. If not, downside risk is real.

Bucket 2 – Add These to Go Deeper These names round out the basket if you want broader exposure. It’s a mix of small-cap volatility and large-cap stability.

Hyperfine (HYPR): $127M market cap HYPR provides the only FDA-cleared portable brain MRI system on the market – its Swoop device, which brings imaging directly to the bedside.

HYPR’s reach is beginning to expand beyond the U.S. Just this year, the startup received approval in India to sell its devices, opening up a large new market.

HYPR is one of the smallest small-caps on this list. And it always trades on news.

With that approval and a surge in value since March, HYPR remains one of the best early land-grab opportunities in this basket.

How I’d Play It Add HYPR for direct brain imaging exposure. Watch upcoming guidance for signs of international traction.

NVIDIA (NVDA): $5.6T market cap Most investors own NVIDIA for AI, but few connect it to the brain race. That’s about to change.

NVIDIA’s Holoscan is an important application in the brain imaging race. For those who don’t know, it’s an AI-enabled sensor processing platform designed for real-time edge computing that can be deployed in various use cases – from security applications to the medical field.

Many of the top BCI players are building their tech on top of NVIDIA’s Holoscan. BCI manufacturer Synchron’s interface runs on NVIDIA Holoscan. And another BCI startup, Merge Labs, is expected to train models on its chips.

Regardless of which platform wins, NVIDIA sits upstream.

How I’d Play It If you already own it, you have exposure. If not, this is another reason to consider it.

Micron (MU): $560B market cap This is the memory bottleneck trade. Compute has scaled far faster than memory over the last three decades. That gap is becoming critical for both AI and brain emulation.

Micron is the clearest U.S.-listed play on high-bandwidth memory. And with so many clients for its chips already being participants in the modern brain race, this stock is one of the best ways to gain early exposure today.

How I’d Play It It’s cyclical. Look to buy on weakness.

Medtronic (MDT): $100B market cap Medtronic partnered with Precision Neuroscience, gaining exposure to BCIs without building the technology internally.

That’s a massive edge in a market where the biggest BCI makers are still dealing with major cost overruns and costly implementation failures.

Medtronic is already a giant in the space. With this partnership in place, MDT represents a more conservative way to trade the theme.

How I’d Play It Useful for portfolios seeking income and lower volatility with some upside optionality.

Nautilus Biotechnology (NAUT): $331.6M market cap This stock is a complementary play to QSI. NAUT approaches protein sequencing differently but targets the same bottleneck. And a recent partnership with Baylor College adds early validation.

How I’d Play It Smaller position than QSI. Treat both as a paired bet.

Bruker (BRKR): $5.56B market cap This is a “picks and shovels” name that’s been setting off my UOA Monitor for weeks.

In fact, I just recently recommended the trade on Masters in Trading LIVE  as the perfect way to gain early exposure to the BCI trend.

This stock already has massive penetration in the space. Its microscopy systems are used across leading brain-mapping labs. It’s a medium-sized player with a lot of room to run.

How I’d Play It A more stable position relative to smaller biotech names.

Thermo Fisher (TMO): $174.5B market cap One of only two companies globally producing the high-throughput electron microscopes used in connectomics research. A long-term compounder.

How I’d Play It A steady, long-duration hold with lower volatility.

Broadcom (AVGO): $2.01T market cap AVGO provides custom AI chips and networking infrastructure for hyperscalers. While not a direct BCI play, it supports the systems that make brain-scale computation possible.

How I’d Play It Similar to NVIDIA—core infrastructure exposure.

Bucket 3 – Watching, But Not Yet Public These are private companies to monitor for IPO activity. When one files, expect ripple effects across the entire basket.

Neuralink
Private: ~$9B valuation Elon Musk’s BCI company has twelve patients implanted. So far, it’s one of the most regulatorily compliant and well capitalized names in the space, already backed by FDA Breakthrough Device designation.

How I’d Play It Not publicly tradable yet. When it files, expect rapid repricing across related equities.

Synchron
Private: Pre-IPO Synchron offers a less invasive interface delivered via the jugular vein – all backed by Jeff Bezos and Bill Gates. As I alluded to at the top, Synchron also has several major partnerships in place with companies like NVIDIA and Apple Vision Pro.

HOW I’D PLAY IT Watch for IPO filing. Potentially lower-risk than Neuralink due to its approach.

Precision Neuroscience
Private: Pre-IPO Precision is working on a surface-level brain interface developed by a former Neuralink engineer. And it just recently received FDA clearance and partnered with Medtronic – all great signs as it works its way to a potential IPO.

How I’d Play It Indirect exposure exists through Medtronic. Consider direct exposure if it goes public.

Colossal Biosciences
Private: Pre-IPO Colossal is connected to Harvard geneticist George Church. While it’s not a pure BCI play, the company is part of a broader biotech ecosystem that could intersect with neural research.

How I’d Play It Highly speculative. Monitor for developments.

One last note: I’m long QSI. I do not currently hold the other names listed here. This reflects my research and watchlist—not a recommendation to buy or sell any security. Small-cap stocks in this space can be highly volatile. Do your own research and consult a licensed professional before investing.

What Happens Next History shows that when a complex problem becomes a matter of engineering—when it can be broken down into discrete constraints—capital flows to the solutions. And that all happens often before the broader narrative fully takes hold.

Today, much of this ecosystem remains underfollowed and, in some cases, mispriced relative to its potential role in the broader shift.

That won’t last.

As progress in these underlying technologies becomes more visible — through partnerships, breakthroughs, and eventually public listings — the market will connect the dots.

When it does, the repricing is unlikely to be gradual.

For investors, the takeaway is straightforward: Focus less on the outcome and more on what must happen for that outcome to exist.

That’s where the opportunity is today.

And if you’re interested in learning more about the system that discovered all these names…

That knowledge is waiting for you inside the Masters in Trading Options Challenge.

The Challenge is where we take everything you’ve learned in my articles and daily LIVEs — fixed risk, thesis-driven exits, laddered entries, defined-duration trades, and emotional discipline — and put it into practice in a structured, step-by-step environment.

For seven days, we walk through the foundations of real options trading the way I learned them on the trading floor. You’ll learn exactly how I think, exactly how I build trades, and exactly how I manage both the winners and the losers.

Just click here to check out what the Masters in Trading Options Challenge has in store for you.

Remember, the creative trader wins.

Jonathan Rose,

Founder, Masters in Trading

P.S. In a recent beta test, TradeSmith CEO Keith Kaplan’s new signals-based approach produced gains in just days — not months. Now, for a limited time, you can explore the same system yourself and see what it’s flagging right now across the market. To get a firsthand look at the same AI Signals system Keith uses — including the top signals of the day and detailed data on any stock you search — watch the full presentation here.

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026.

Frank H. Laukien, Bruker’s President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bill ratio was again greater than 1.0x. Healthy bookings trends included solid academic orders for our post-genomic research solutions from outside the US, strong AI-driven demand in semiconductor metrology and in SciY laboratory software, bookings strength in industrial research tools and security detection systems.”

He continued: “Importantly, we have introduced impactful new products and solutions at recent scientific and medical conferences, further strengthening our leadership position in NMR, leading the way in spatial biology, and innovating in microbiology and molecular diagnostics. With increased visibility, we reconfirm our FY26 guidance, and we expect a return to organic revenue growth in Q2. All in, Bruker remains poised to deliver significant operating margin expansion and double-digit EPS growth in FY2026.”

First Quarter 2026 (Q1-26) Financial Results

Bruker’s revenues for the first quarter of 2026 were $823.4 million, an increase of 2.7% compared to $801.4 million in the first quarter of 2025. In Q1-26, revenues decreased organically by 4.4% yoy, while growth from acquisitions was 2.6%, and foreign currency translation had a favorable impact of 4.5% yoy.

Q1-26 Bruker Scientific Instruments (BSI) revenues of $759.8 million increased 2.1% yoy, with organic revenue decreasing by 5.0%. Q1-26 Bruker Energy & Supercon Technologies (BEST) revenues of $66.9 million increased 12.8% yoy, with an organic revenue increase of 3.0%, net of intercompany eliminations.

Q1-26 GAAP operating income was $10.2 million, compared to GAAP operating income of $31.8 million in the first quarter of 2025. Bruker's Q1-26 non-GAAP operating income was $84.2 million, compared to $101.7 million in the first quarter of 2025, and Q1-26 non-GAAP operating margin was 10.2%, compared to 12.7% in the first quarter of 2025.

Q1-26 GAAP diluted earnings per share was $0.02, compared to diluted earnings per share of $0.11 in the first quarter of 2025. Q1-26 non-GAAP diluted EPS was $0.31, compared to $0.47 in the first quarter of 2025.

Reconfirming Previous Fiscal Year 2026 (FY26) Financial Outlook

Bruker continues to expect FY26 revenues of $3.57 to $3.60 billion, compared to FY25 revenues of $3.44 billion, with 4% to 5% year-over-year reported revenue growth, including:

Organic revenue growth of 1% to 2%, M&A revenue growth contribution of approximately 1.5%, and Foreign currency translation revenue tailwind of approximately 1.5% Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15, compared to $1.83 in FY25, an increase of 15% to 17% year-over-year. This includes a currency headwind of approximately $0.15, or 8%, implying constant exchange rate (CER) non-GAAP EPS growth of 23% to 25% yoy.

Our FY26 revenue and non-GAAP EPS guidance is based on foreign currency exchange rates as of March 31, 2026.

For the Company’s outlook for 2026 organic revenue growth, M&A revenue growth, constant exchange rate revenue growth, and constant exchange rate non-GAAP EPS growth, and non-GAAP EPS, each of which are forward-looking non-GAAP measures, we are not able to provide without unreasonable effort the most directly comparable GAAP financial measures, or reconciliations to such GAAP financial measures on a forward-looking basis. Please see “Use of Non-GAAP Financial Measures” below for a description of items excluded from our expected non-GAAP EPS.

Quarterly Earnings Call

Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today, May 6, 2026, at 8:00 am Eastern Daylight Time. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink. A slide presentation will be referenced during the webcast and will be posted to our Investor Relations website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s First Quarter 2026 Earnings Conference Call”.

Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit https://dpregister.com/sreg/10208837/103f221d07a and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call.

A telephone replay of the conference call will be available by dialing 1-855-669-9658 (U.S. toll free) or +1-412-317-0088 (international) and entering replay access code: 6572958. The replay will be available beginning one hour after the end of the conference call through June 6, 2026.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in specialty diagnostics, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Use of Non-GAAP Financial Measures

To supplement our consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we use the following non-GAAP financial measures: non-GAAP gross profit; non-GAAP gross profit margin; non-GAAP operating income; non-GAAP operating income margin; non-GAAP SG&A expense; non-GAAP interest and other income (expense), net; non-GAAP profit before income taxes; non-GAAP income tax rate; non-GAAP net income and non-GAAP diluted earnings per share. These non-GAAP measures exclude costs related to restructuring actions, impairments, acquisition and related integration expenses, amortization of acquired intangible assets, and other non-operational costs.

We also may refer to CER currency revenue growth, CER non-GAAP EPS growth, and free cash flow which are also non-GAAP financial measures. We define the term CER currency revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates. We define the term CER EPS as non-GAAP EPS excluding the effect of changes in foreign currency translation rates. We define free cash flow as net cash provided by operating activities, less additions to property, plant, and equipment. We believe free cash flow is a useful measure to evaluate our business because it indicates the amount of cash generated after additions to property, plant, and equipment that is available for, among other things, acquisitions, investments in our business, repayment of debt and return of capital to shareholders.

The presentation of these non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies. We believe these non-GAAP financial measures provide meaningful supplemental information regarding our performance. However, we urge investors to review the reconciliation of these financial measures to the comparable GAAP financial measures included in the accompanying tables, and not to rely on any single financial measure to evaluate our business. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance.

We use these non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting for certain items that are not reflective of the underlying performance of our business. These measures may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results. We regularly use these non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on certain non-GAAP measures and use this information for our planning and forecasting activities.

Additional information relating to the non-GAAP financial measures used in this press release and reconciliations to the most directly comparable GAAP financial measures are provided in the tables accompanying this press release following our GAAP financial statements.

With respect to our outlook for 2026 non-GAAP organic revenue, non-GAAP M&A revenue, and non-GAAP EPS, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GAAP financial measures on a forward-looking basis, because we are unable to predict with reasonable certainty certain items that may affect such measures calculated and presented in accordance with GAAP without unreasonable effort. Our expected non-GAAP organic revenue and EPS ranges exclude primarily the future impact of restructuring actions, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments. These reconciling items are uncertain, depend on various factors outside our management’s control and could significantly impact, either individually or in the aggregate, our future revenues and EPS presented in accordance with GAAP.

Forward-Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2026 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin improvements, foreign currency translation revenue impact, EPS, non-GAAP EPS, and CER Non-GAAP EPS growth; effects of academic market and tariff dynamics on our future financial results and our ability to mitigate such effects in the future; management’s expectations for the impact of foreign currency and acquisitions; the effects of our expanded cost savings initiatives; and for future financial and operational performance and business outlook; future economic conditions; and statements found under the “Use of Non-GAAP Financial Measures” section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, (1) the length and severity of any recession and the impact on global economic conditions, (2) the impact of supply chain challenges, including inflationary pressures, (3) the impact of geopolitical instability and tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from the ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, (4) the conflict in Israel, Palestine and surrounding areas and hostilities in the Middle East, including heightened tensions in Iran, and the possible expansion of such conflicts and potential geopolitical consequences and global instability, (5) the ongoing tensions between the United States and China, tariff increases or uncertainties and trade policy changes and restrictions, and the increasing potential of conflict involving countries in Asia that are critical to our supply chain operations, such as Taiwan and China, (6) continued volatility in the capital markets, (7) the impact of increased interest rates, (8) the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, (9) our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, (10) the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, (11) changes in governmental regulations, intellectual property rights, and litigation, (12) exposure to foreign currency fluctuations, (13) the impact of foreign currency exchange rates, (14) our ability to service our debt obligations and fund our anticipated cash needs, (15) the effect of a concentrated ownership of our common stock, (16) the loss of key personnel, (17) payment of future dividends, (18) the impact (if any) of macroeconomic issues, including uncertainties related to trade policies or tariff regulations, and (19) other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by applicable law.

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

(in millions, except per share data)

  Three Months Ended
March 31,

2026

2025

Revenue

$

823.4

$

801.4

Cost of revenue

443.6

410.2

Gross profit

379.8

391.2

Operating expenses:

Selling, general and administrative

242.1

225.4

Research and development

101.3

97.1

Other charges, net

26.2

36.9

Total operating expenses

369.6

359.4

Operating income

10.2

31.8

Interest and other income (expense), net

11.7

(6.7

)

Income before income taxes, equity in (losses) income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries (a)

21.9

25.1

Income tax provision

2.5

8.7

Equity in (losses) income of unconsolidated investees, net of tax

(3.7

)

0.4

Consolidated net income

15.7

16.8

Net income (loss) attributable to noncontrolling interests in consolidated subsidiaries

1.3

(0.6

)

Net income attributable to Bruker Corporation

$

14.4

$

17.4

Dividends on Series A Mandatory Convertible Preferred Stock

10.9

—

Net income attributable to Bruker Corporation common shareholders

$

3.5

$

17.4

Net income per common share attributable to Bruker Corporation common shareholders:

Basic

$

0.02

$

0.11

Diluted

$

0.02

$

0.11

Weighted average common shares outstanding:

Basic

152.2

151.6

Diluted

152.7

151.9

  a) On subsequent pages this is referred to as “Profit before income tax”.

Bruker Corporation

REVENUE

(unaudited and in millions)

  Three Months Ended
March 31,

2026

2025

Revenue by Segment:

Bruker BioSpin

$

197.5

$

207.8

Bruker CALID

316.3

280.1

Bruker Nano

246.0

256.6

BSI Revenue Total

759.8

744.5

BEST

66.9

59.3

Eliminations

(3.3

)

(2.4

)

Total revenue

$

823.4

$

801.4

Revenue by End Customer Geography:

United States

$

221.9

$

217.4

Europe

321.6

285.2

Asia Pacific

208.7

232.6

Other

71.2

66.2

Total revenue

$

823.4

$

801.4

Bruker Corporation
RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES
(unaudited and in millions, except per share data)

The tables below present the GAAP to Non-GAAP reconciliation for the three months ended March 31, 2026, and March 31, 2025, respectively, for the following measures: Gross Profit and Gross Profit Margin; Selling, General and Administrative (“SG&A”) Expenses; Operating Income and Operating Income Margin; Interest and Other Income (Expense), net; Profit before Income Taxes; Net Income Attributable to Bruker Corporation Common Shareholders; Diluted net income per common share; and Income Tax rate.

Gross Profit

Gross Profit Margin

SG&A Expenses

Operating Income

Operating Income Margin

Interest and other income (expense), net

Profit before income tax (a)

Net Income attributable to Bruker Corporation Common Shareholders

Diluted net income per common share

Income Tax Rate

Three Months Ended March 31, 2026:

GAAP

$

379.8

46.1

%

$

242.1

$

10.2

1.2

%

$

11.7

$

21.9

$

3.5

$

0.02

11.4

%

Non-GAAP adjustments:

Restructuring costs

9.5

1.2

%

—

17.8

2.2

%

—

17.8

17.8

0.12

—

Acquisition-related costs

3.4

0.4

%

—

7.5

0.9

%

—

7.5

7.5

0.05

—

Purchased intangibles amortization

16.7

2.0

%

(15.7

)

32.5

3.9

%

—

32.5

32.5

0.21

—

Intangible assets impairment charges

0.7

0.1

%

—

2.7

0.3

%

—

2.7

2.7

0.02

—

Gain on remeasurement of previously held equity interest

—

—

—

—

—

(12.2

)

(12.2

)

(12.2

)

(0.08

)

Investments related adjustments

—

—

—

—

—

(1.2

)

(1.2

)

(1.2

)

(0.01

)

—

Lease and fixed asset impairment charges

1.8

0.2

%

—

12.7

1.5

%

—

12.7

12.7

0.08

—

Other costs

(0.1

)

—

—

0.8

0.2

%

—

0.8

0.8

0.01

—

Tax effect of above Non-GAAP adjustments

—

—

—

—

—

—

—

(20.3

)

(0.13

)

16.2

%

Equity in income (losses) of unconsolidated investees, net of tax

—

—

—

—

—

—

—

3.7

0.02

—

Noncontrolling interests related to non-GAAP adjustments

—

—

—

—

—

—

—

(0.5

)

—

—

Total Non-GAAP adjustments

32.0

3.9

%

(15.7

)

74.0

9.0

%

(13.4

)

60.6

43.5

0.29

16.2

%

Non-GAAP

$

411.8

50.0

%

$

226.4

$

84.2

10.2

%

$

(1.7

)

$

82.5

$

47.0

$

0.31

27.6

%

Three Months Ended March 31, 2025:

GAAP

$

391.2

48.8

%

$

225.4

$

31.8

4.0

%

$

(6.7

)

$

25.1

$

17.4

$

0.11

34.7

%

Non-GAAP adjustments:

Restructuring costs

2.6

0.3

%

—

10.2

1.3

%

—

10.2

10.2

0.07

—

Acquisition-related costs

2.3

0.3

%

—

8.6

1.1

%

—

8.6

8.6

0.06

—

Purchased intangibles amortization

14.0

1.7

%

(13.1

)

27.3

3.4

%

—

27.3

27.3

0.18

—

Acquisition-related litigation charges

—

—

—

18.6

2.3

%

—

18.6

18.6

0.12

—

Investments related adjustments

—

—

—

—

—

2.0

2.0

2.0

0.01

—

Other costs

0.8

0.2

%

—

5.2

0.6

%

—

5.2

5.2

0.03

—

Tax effect of above Non-GAAP adjustments

—

—

—

—

—

—

—

(18.2

)

(0.11

)

(0.6

)%

Other Discrete Items

—

—

—

—

—

—

—

—

—

(6.4

)%

Equity in income (losses) of unconsolidated investees, net of tax

—

—

—

—

—

—

—

(0.4

)

—

—

Total Non-GAAP adjustments

19.7

2.5

%

(13.1

)

69.9

8.7

%

2.0

71.9

53.3

0.36

(7.0

)%

Non-GAAP

$

410.9

51.3

%

$

212.3

$

101.7

12.7

%

$

(4.7

)

$

97.0

$

70.7

$

0.47

27.7

%

Bruker Corporation
RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES - Continued
(unaudited and in millions, except per share data)

The tables below present the GAAP to Non-GAAP reconciliation for weighted average common shares outstanding (Diluted), CER currency revenue, organic revenue, and free cash flow:

Three Months Ended
March 31,

2026

2025

GAAP Weighted Average Common Shares Outstanding (Diluted)

152.7

151.9

Stock options, restricted stock units, and employee stock purchase plan

—

—

Series A Mandatory Convertible Preferred Stock (a)

—

—

Non-GAAP Weighted Average Common Shares Outstanding (Diluted)

152.7

151.9

Total Bruker

Bruker Scientific Instruments (a)

BEST

Three Months Ended March 31,

2026

yoy growth (c)

2025

2026

yoy growth (c)

2025

2026

yoy growth (c)

2025

GAAP revenue

$

823.4

2.7%

$

801.4

$

759.8

2.1%

$

744.5

$

63.6

11.8%

$

56.9

Effect of changes in foreign currency translation rates

36.6

(10.4

)

31.6

(9.2

)

5.0

(1.2

)

Non-GAAP CER currency revenue

786.8

(1.8)%

811.8

728.2

(2.2)%

753.7

58.6

3.0%

58.1

Acquisitions (b)

20.8

69.2

20.8

69.2

-

-

Non-GAAP Organic revenue

$

766.0

(4.4)%

$

742.6

$

707.4

(5.0)%

$

684.5

$

58.6

3.0%

$

58.1

Three Months Ended
March 31,

2026

2025

Net cash provided by operating activities

$

71.2

$

65.0

Non-GAAP adjustments:

Purchases of property, plant and equipment

(24.2

)

(26.0

)

Non-GAAP free cash flow

$

47.0

$

39.0

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in millions)

  March 31,
2026

December 31,
2025

ASSETS

Current assets:

Cash and cash equivalents

$

133.4

$

298.8

Accounts receivable, net

542.7

544.9

Inventories

1,121.5

1,094.6

Other current assets

306.0

274.2

Total current assets

2,103.6

2,212.5

Property, plant and equipment, net

719.6

744.8

Goodwill, intangibles, net and other long-term assets

3,307.5

3,284.1

Total assets

$

6,130.7

$

6,241.4

LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS’ EQUITY

Current liabilities:

Current portion of long-term debt and finance lease obligations

$

8.4

$

16.6

Accounts payable

269.1

215.9

Deferred revenue and customer advances

479.7

441.3

Other current liabilities

597.9

605.4

Total current liabilities

1,355.1

1,279.2

Long-term debt

1,662.9

1,852.5

Other long-term liabilities

609.9

599.4

Redeemable noncontrolling interests

35.8

36.8

Total shareholders' equity

2,467.0

2,473.5

Total liabilities, redeemable noncontrolling interests and shareholders' equity

$

6,130.7

$

6,241.4

Bruker Corporation

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(in millions)

  Three Months Ended
March 31,

2026

2025

Cash flows from operating activities:

Consolidated net income

$

15.7

$

16.8

Adjustments to reconcile consolidated net income to cash flows from operating activities:

Depreciation and amortization

58.3

50.4

Other non-cash expenses, net

21.4

(11.5

)

Changes in operating assets and liabilities, net of acquisitions and divestitures:

Accounts payable and accrued expenses

11.2

26.4

Inventories

(47.2

)

(28.4

)

Other changes in operating assets and liabilities, net

11.8

11.3

Net cash provided by operating activities

71.2

65.0

Cash flows from investing activities:

Purchases of property, plant and equipment

(24.2

)

(26.0

)

Cash paid for acquisitions, net of cash acquired

(16.0

)

(1.1

)

Other investing activities, net

0.5

1.0

Net cash used in investing activities

(39.7

)

(26.1

)

Cash flows from financing activities:

Repayments of revolving lines of credit

—

(167.9

)

Proceeds from revolving lines of credit

—

139.9

Repayment of long-term debt

(181.3

)

(7.7

)

Proceeds from long-term debt

—

2.9

Payment of dividends to Series A Mandatory Convertible Preferred Shareholders

(11.0

)

—

Payment of dividends to common shareholders

(7.6

)

(7.7

)

Repurchase of common stock

—

(10.0

)

Other financing activities, net

(5.0

)

(0.7

)

Net cash used in financing activities

(204.9

)

(51.2

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

7.9

13.3

Net increase (decrease) in cash, cash equivalents and restricted cash

(165.5

)

1.0

Cash, cash equivalents and restricted cash at beginning of period

303.1

186.7

Cash, cash equivalents and restricted cash at end of period

$

137.6

$

187.7

Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue micro.

At ASMS, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separati